Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Amicus Therapeutics Inc | FOLD | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
9.80 |
Trades | Shares Traded | Average Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 9.02 - 14.57 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
- | 0 | US$ 9.80 | USD |
Amicus Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.89B | 295.38M | - | 399.36M | -151.58M | -0.51 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Amicus Therapeutics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FOLD Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 9.74 | 10.00 | 9.28 | 9.69 | 2,126,939 | 0.06 | 0.62% |
1 Month | 10.39 | 10.57 | 9.02 | 9.63 | 2,671,644 | -0.59 | -5.68% |
3 Months | 12.32 | 12.44 | 9.02 | 10.70 | 2,810,210 | -2.52 | -20.45% |
6 Months | 11.13 | 14.57 | 9.02 | 11.98 | 3,082,769 | -1.33 | -11.95% |
1 Year | 12.07 | 14.57 | 9.02 | 12.06 | 2,749,309 | -2.27 | -18.81% |
3 Years | 9.51 | 14.57 | 5.91 | 10.95 | 2,703,293 | 0.29 | 3.05% |
5 Years | 11.30 | 25.39 | 5.91 | 11.54 | 2,737,429 | -1.50 | -13.27% |
Amicus Therapeutics Description
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. |